Why aveo Is Trending Today?

Aveo Pharmaceuticals, Inc. Announces Positive Top-Line Results from Phase 3 Trial of Tivozanib in Metastatic Renal Cell Carcinoma; Aveo to Host Conference Call Today. Aveo Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update. Aveo Pharmaceuticals to Present at the 2016 American Society of Clinical Oncology Annual Meeting.

Aveo Capital Partners LLC has recently increased its stake in various ETFs, including the PIMCO Multi Sector Bond Active ETF (PYLD), Dimensional International Value ETF (DFIV), and Dimensional US Small Cap Value ETF (DFSV). The firm has also initiated new positions in several ETFs such as the iShares S&P 100 ETF (OEF), ProShares Ultra MSCI Emerging Markets ETF (EET), and Schwab Fundamental International Equity ETF (FNDF). Additionally, Aveo Capital Partners LLC has grown its stock holdings in ETFs like the Vanguard Russell 1000 ETF (VONE), JPMorgan Municipal ETF (JMUB), and VanEck Intermediate Muni ETF (ITM), while also increasing its position in the Dimensional International Core Equity 2 ETF (DFIC). However, the firm has also sold shares of the Dimensional Emerging Markets Value ETF (DFEV).